mln-2238

Ixazomib (MLN2238) , a second generation, boron-containing peptide proteasome inhibitor (PI), inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome (IC50/Ki: 3.4/0.93 nM, in cell-free assays), also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50: 31/3500 nM).

Ixazomib-d7 is a deuterium-labeled version of Ixazomib. Ixazomib (MLN2238) is a potent, selective, and reversible proteasome inhibitor. It targets the chymotrypsin-like proteolytic site (β5) of the 20S proteasome, with an IC50 value of 3.4 nM and a Ki of 0.93 nM.

Ixazomib citrate (MLN9708) is a prodrug of Ixazomib (MLN-2238) and an orally bioavailable second-generation proteasome inhibitor with an IC50 of 3.4 nM, exhibiting potential antineoplastic activity.